Latest news
- Business23 June 2022
Adalvo is now offering over 100 products to our partners!
Adalvo is now able to offer over 100 tailor-made products to our partners. As part of our growth journey, our focus has always been to bring high-value, differentiated products, covering...
- Business21 June 2022
Adalvo Announces Successful BE Outcome for Tafamidis Meglumine 20mg Soft Gel Capsules
We are pleased to announce that we have now completed our Pivotal BE program for Tafamidis Meglumine Soft Gel Capsules 20mg.
- Business16 June 2022
Apremilast Film-Coated Tablets: DCP Status Update
Adalvo is pleased to announce that our dossier for Apremilast Film-Coated Tablets is complete and our DCP submission is scheduled for January 2023.
- Business14 June 2022
Adalvo Announces Successful Pivotal BE Program For Macitentan 10mg Film-Coated Tablets
We are pleased to announce that we have now completed our Pivotal BE program for Macitentan 10mg film-coated tablets. This product has been developed in collaboration with one of our strategic...
- Business08 June 2022
Vortioxetine Film-Coated Tablets: DCP Submission Timeline Update
Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked for the15th July 2022.
- Business02 June 2022
Cladribine: Adalvo makes good progress on a challenging development
We are pleased to announce the successful progression of Cladribine, which is being developed based on the reference brand Mavenclad (Merck) and is indicated in the treatment of Multiple Sclerosis....
- Business19 May 2022
Women Health Segment: Why is Adalvo a partner of choice?
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are now developing...
- Business11 May 2022
Adalvo announces DCP approval for Enzalutamide Soft Gel capsules
Adalvo is delighted to announce the successful EU DCP closure of our Enzalutamide Soft Gel Capsules. We believe to be the first Company to receive an EU approval, and with this...
- Business10 May 2022
A Powerful Investment Alliance of Aztiq and Innobic Acquires Alvogen Shares in Adalvo
The Consortium jointly, through Aztiq II HoldCo, has acquired a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholder in Adalvo. The Consortium’s collective industry experience,...
- Business28 April 2022
Adalvo advances in diabetes space, offering injectable and oral treatment alternatives
Adalvo is one of the few companies who can offer a comprehensive diabetes portfolio covering small molecule oral treatments and complex peptide injectables. We understand that diabetes is becoming one of the fast-growing diseases, and...
- Achievements21 April 2022
Adalvo Wins the Most Innovative B2B Pharmaceutical Company, 2022 (Europe) Award
We are humbled and honored to have been recognized by Global Health and Pharma Magazine's 2022 Global Excellence Awards and have been awarded the title of: Most Innovative B2B Pharmaceutical Company, 2022...
- Business19 April 2022
Adalvo aims to launch Gabapentin ER, a branded value-added product, in Q1 2023
We are proud to announce that our distinguished hybrid / 505(b)(2) asset Gralise® has reached an advanced stage and that Adalvo will move into launch in Q1 2023. With this achievement we add a...
- Business13 April 2022
Dalbavancin: Dossier Readiness In Q4 2022
As we strengthen our injection product pipeline, we are pleased to provide a status update on our development of Dalbavancin. The development of this complex niche generic is progressing very...
- Business08 April 2022
Adalvo advances in Dermatology space with a basket of specialty products
As we continue to deliver on our brand promise of being the preferred partner and setting a new standard for the future of Pharma, Adalvo provides various solutions and differentiated...
- Business05 April 2022
Adalvo announces DCP submission date for Vortioxetine Film-Coated Tablets
Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked and the submission will be completed in July 2022.
- Business29 March 2022
Adalvo announces successful Pivotal BE outcome of Apremilast
We are pleased to announce that we have now completed our Pivotal BE program for Apremilast Film-Coated Tablets. This product has been developed in collaboration with one of our strategic...
- Business23 March 2022
Eribulin: DCP slot booked for August 2022
We are pleased to provide a status update on our development of Eribulin injection 0.44mg/ml. The development of this product is progressing very well; our dossier will be available for...
- Business17 March 2022
Adalvo announces successful Pivotal BE outcome of Midostaurin Capsules 25mg
We are pleased to announce that, following the successful completion of our ANDA for Midostaurin Capsules 25mg in the US, we have now completed our Pivotal BE program in Europe....
- Business15 March 2022
Adalvo announces US dossier readiness of Semaglutide 1.34mg/ml pre-filled pen
We are pleased to announce that our US dossier of Semaglutide 1.34mg/ml pre-filled pen is ready and available for licensing in Ex-US markets. We will now move full steam...
- Business09 March 2022
Adalvo announces commencement of DCP procedure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet
Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst...
- Business28 February 2022
Aztiq partners with SK Pharma to create Arphio, a new business entity dedicated solely to orphan and rare disease medicines
Aztiq is thrilled to announce the recent establishment of a new entity Arphio a venture initiated in close collaboration with SK Pharma.